

IMAGINE THIS:

**A WAY TO
HELP RESTORE
WHAT'S YOURS**




Understanding Vitiligo

Vitiligo develops in genetically susceptible individuals when environmental triggers induce stress responses in the skin. This causes an autoimmune response in which melanocytes (pigment-producing cells in the skin)

are targeted and destroyed by the body's own "killer T cells" (CD8⁺ T-cells). The JAK-STAT pathway plays a central role in this process.¹⁻²

JAK-STAT activation and inflammatory cycle triggering the attack on melanocytes.



This leads to melanocyte death and depigmentation.





Illustration adapted from Reference 8.

The Process of Repigmentation

Repigmentation may occur once the inflammatory response is suppressed and melanocyte precursors are stimulated to proliferate, migrate, and become mature melanocytes which can slowly begin to produce pigment.³

The main sources of melanocytes and melanocyte precursors are the hair follicles and the epidermis at the lesion borders.³ The precise molecular and cellular mechanisms underlying vitiligo repigmentation remain to be confirmed.¹



Repigmentation is a gradual process that can take weeks to months depending on the location of the lesion on the body.³

Illustration adapted from Reference 8.

Repigmentation occurs most quickly in areas with a greater density of hair follicles³:

Higher density of hair follicles
More rapid repigmentation³

Face, arms, forearms,
thighs, legs, abdomen,
back



Medium density of hair follicles
Slower repigmentation³

Back of hands, fingers,
feet, toes



Low density of hair follicles
Rarely repigment³

Palms, soles, inner-side of
wrists, genitals, mucosal or
semimucosal surfaces,
areas with white terminal
hairs



What is Lumirix®

Lumirix® contains the active substance Ruxolitinib, a Janus kinase (JAK) inhibitor.⁶

Lumirix® is free from steroids.⁶

Lumirix® is used on the skin to treat non-segmental vitiligo with facial involvement in adults and adolescents from 12 years.⁶



How does Lumirix® work?

Ruxolitinib blocks the JAK/STAT pathway, inhibiting the body's attack against the melanin-producing cells. This allows the skin to produce pigment and regain its normal colour.⁵





Illustration adapted from Reference 8.



Starting Lumirix®



Apply a thin layer of cream twice daily to the affected areas of your skin.⁶

Wait at least 8 hours between applications.⁶

The cream should not be used on more than 10% of your body. Do not use more than 2 tubes of Lumirix® 100g in a month.⁶

Your doctor will recommend a treatment plan for you including how long you should use the cream.

The re-pigmentation process varies for each patient but would require months of continuous treatment.

It is important that you adhere to the prescribed dosing regimen for optimal results. Typically, you should be able to see repigmentation from 3 months onwards.⁷

Maintaining your results

Once you have achieved your treatment goal, speak to your doctor about how to maintain re-pigmentation and prevent relapse.



 **Lumirix[®]**
Ruxolitinib Cream 15mg/g

For more information, please consult your physician.

This brochure is intended to be distributed to patients prescribed with Lumirix[®] cream by their physician.

 **RXILIENT**

c/o Luqa Business Development Limited

RM 2106, 21/F, Island Place Tower, No. 510 King's Road,
North Point, Hong Kong

References: 1. Frisoli ML, et al. 'Vitiligo: Mechanisms of Pathogenesis and Treatment'. Annual Review of Immunology 2020;38:621-48. 2. Qi F, Liu F, Gao L. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review. Front Immunol. 2021 Nov 18;12:790125. 3. Birlea SA, Goldstein NB, Norris DA. Repigmentation through melanocyte regeneration in vitiligo. Dermatol Clin. 2017;35(2):205-218. doi:10.1016/j.det.2016.11.015. 4. Utama A, et al. 'Janus Kinase Inhibitors and the Changing Landscape of Vitiligo Management: A Scoping Review'. International Journal of Dermatology 2024;63:1020-35. 5. Hwang JR, Driscoll MS. Review of Ruxolitinib for Treatment of Non-Segmental Vitiligo. Annals of Pharmacotherapy. 2023;57(8):948-955 6. Hong Kong Lumirix[®] cream Prescribing Information. 7. Rosmarin D, et al. 'Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo'. The New England Journal of Medicine 2022;387:1445-55. 8. Incyte. "Discover The role of The Jak-stat Pathway in vitiligo." Accessed Jan 22, 2025. <https://www.vitiligodeeper.com/jak-stat-pathway>.

LUM/HKG/DOC-065/2024/rev.01

想像一下:

重拾屬於您的




了解白蝕症

當環境因素誘發皮膚壓力反應時，遺傳風險較高的人士會有機會出現白蝕症。這會引起自體免疫反應，當中黑色素細胞

(皮膚中產生色素的細胞) 被人體自身的「細胞毒性T細胞」(CD8+ T 細胞)攻擊並破壞。 JAK-STAT 路徑在此過程中扮演重要角色。¹⁻²

JAK-STAT的啟動和炎症性的循環觸發對黑色素細胞的攻擊。

導致黑色素細胞死亡和色素脫失。




插圖改編自參考文獻 8。

色素恢復的過程

一旦發炎反應被抑制，黑色素細胞前驅細胞被刺激增生、遷移並成為成熟的黑色素細胞，可慢慢開始產生色素進行修復。³

黑色素細胞和黑色素細胞前驅細胞的主要來源是毛囊和病變位置邊界的表皮。³白蝕症背後精確的分子和細胞機制仍有待確認。¹



色素恢復是一個漸進的過程，可能需要數週到數月的時間，具體時間取決於身體病變的位置。³

插圖改編自參考文獻 8。

在毛囊密度較高的區域，色素恢復較快³：

較高毛囊密度的部位
較快恢復色素³

臉，手臂，前臂，
大腿，腿，背部



中等毛囊密度的部位
較慢恢復色素³

手背，手指，腳，腳趾



較低毛囊密度的部位
很少恢復色素³

手掌，腳底，
手腕內側，
生殖器，黏膜或半黏膜表面，
毛髮已變白的區域



Lumirix®是什麼？

Lumirix® 含有活性成分 Ruxolitinib，一種JAK激酶抑制劑。⁶


Lumirix® 不含類固醇。⁶

Lumirix® 可用於皮膚治療成年及12歲以上青少年患有非節段性面部受累白蝕症的患者。⁶




Lumirix® 的作用原理是什麼？

Ruxolitinib 抑制 JAK/STAT 路徑，從而抑制人體對黑色素生成細胞的攻擊，令皮膚能夠產生色素並恢復其正常顏色。⁵



插圖改編自參考文獻 8。



開始 Lumirix® 治療



每天在受影響的皮膚區域塗抹一層薄薄的藥膏兩次。兩次之間至少相隔8小時。⁶

藥膏的使用面積不得超過身體面積的10%。一個月內不要使用超過 2 支 Lumirix® 100g。⁶

您的醫生將為您推薦治療方案，包括應使用藥膏多長時間。每個患者色素恢復的進展各不相同，但一般需要數月的持續治療。

遵守規定的用藥方案以獲得最佳效果是非常重要的。一般情況下，您應該在 3 個月後能夠看到色素恢復。⁷

維持您的治療目標

一旦您實現了治療目標，請與您的醫生討論如何維持治療效果並防止復發。





Lumirix[®]

Ruxolitinib Cream 15mg/g

欲了解更多資訊，請諮詢您的醫生。

本手冊旨在由醫生派發給已處方Lumirix[®]的患者。



c/o 盧凱業務發展有限公司（代理）

香港北角英皇道510号港運大廈21樓2106

References: 1. Frisoli ML, et al. 'Vitiligo: Mechanisms of Pathogenesis and Treatment'. Annual Review of Immunology 2020;38:621-48. 2. Qi F, Liu F, Gao L. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review. Front Immunol. 2021 Nov 18;12:790125. 3. Birlea SA, Goldstein NB, Norris DA. Repigmentation through melanocyte regeneration in vitiligo. Dermatol Clin. 2017;35(2):205-218. doi:10.1016/j.det.2016.11.015. 4. Utama A, et al. 'Janus Kinase Inhibitors and the Changing Landscape of Vitiligo Management: A Scoping Review'. International Journal of Dermatology 2024;63:1020-35. 5. Hwang JR, Driscoll MS. Review of Ruxolitinib for Treatment of Non-Segmental Vitiligo. Annals of Pharmacotherapy. 2023;57(8):948-955 6. Hong Kong Lumirix[®] cream Prescribing Information. 7. Rosmarin D, et al. 'Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo'. The New England Journal of Medicine 2022;387:1445-55. 8. Incyte. "Discover The role of The Jak-stat Pathway in vitiligo." Accessed Jan 22, 2025. <https://www.vitiligodeeper.com/jak-stat-pathway>.